+

SV2002000036A - Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma - Google Patents

Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma

Info

Publication number
SV2002000036A
SV2002000036A SV2000000036A SV2000000036A SV2002000036A SV 2002000036 A SV2002000036 A SV 2002000036A SV 2000000036 A SV2000000036 A SV 2000000036A SV 2000000036 A SV2000000036 A SV 2000000036A SV 2002000036 A SV2002000036 A SV 2002000036A
Authority
SV
El Salvador
Prior art keywords
hmg
dihydroxyl
reductase
ref
salts
Prior art date
Application number
SV2000000036A
Other languages
English (en)
Inventor
Edward J J Grabowski
Richard D Tillyer
Paul J Reider
Jose M Vega
Feng Xu
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of SV2002000036A publication Critical patent/SV2002000036A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

EL PRESENTE INVENTO OFRECE METODOS Y COMPOSICIONES FARMACEUTICAS PARA LA INHIBICION DE REDUCTASA HMG-CoA, ASI COMO EL TRATAMIENTO Y/O REDUCCION DEL RIESGO DE ENFERMEDADES Y CONDICIONES QUE AFECTAN LA INHIBICION DE REDUCTASA HMG-CoA, QUE COMPRENDE LA ADMINISTRACION ORAL DE UNA CANTIDAD EFECTIVA TERAPEUTICAMENTE DE UN COMPUESTO SELECCIONADO DE UNA ESTATINA DE ACIDO ABIERTO DE DIHIDROXILO Y UNA SAL O ESTER CORRESPONDIENTE FARMACEUTICAMENTE ACEPTABLE EN FORMA DE DOSIS FARMACEUTICA DE LIBERACION RETRASADA A UN PACIENTE QUE NECESITE DICHO TRATAMIENTO, DONDE UNA IMPORTANTE LIBERACION DEL COMPUESTO DE LA DOSIS SE RETRASA HASTA QUE LA DOSIS PASE AL ESTOMAGO.
SV2000000036A 1999-03-08 2000-03-08 Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma SV2002000036A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12322799P 1999-03-08 1999-03-08
US26474499A 1999-03-09 1999-03-09
PCT/US2000/002626 WO2000053173A1 (en) 1999-03-08 2000-02-02 Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors

Publications (1)

Publication Number Publication Date
SV2002000036A true SV2002000036A (es) 2002-02-05

Family

ID=26821357

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2000000036A SV2002000036A (es) 1999-03-08 2000-03-08 Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma

Country Status (9)

Country Link
EP (1) EP1161236A1 (es)
JP (2) JP2002538202A (es)
AR (1) AR022856A1 (es)
AU (1) AU2866400A (es)
CA (1) CA2364253A1 (es)
CO (1) CO5150193A1 (es)
PE (1) PE20001559A1 (es)
SV (1) SV2002000036A (es)
WO (1) WO2000053173A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2389973A1 (en) * 1999-11-04 2001-05-10 Andrx Corporation Method of treating amyloid beta precursor disorders
JP2004508347A (ja) * 2000-09-06 2004-03-18 メルク　エンド　カムパニー　インコーポレーテッド シンバスタチンのジヒドロキシ開環酸塩
AU2001294221B2 (en) * 2000-10-12 2005-09-29 Kowa Company, Ltd. Preventives and remedies for complications of diabetes
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
CA2563051A1 (en) 2001-01-26 2002-08-01 Schering Corporation Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156422A0 (en) 2001-01-26 2004-01-04 Schering Corp The use of substituted azetidinone compounds for the treatment of sitosterolemia
TR200302281T2 (tr) * 2001-08-16 2004-09-21 Teva Pharmaceutical Industries Ltd. Statinlerin kalsiyum tuzu formlarını hazırlamak için işlemler
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ATE345793T1 (de) 2001-09-21 2006-12-15 Schering Corp Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
EP1471930B1 (en) * 2002-01-09 2007-04-11 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
WO2004043456A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
ES2318274T3 (es) 2003-03-07 2009-05-01 Schering Corporation Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
US8987322B2 (en) 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
DE602004020649D1 (de) * 2003-11-07 2009-05-28 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
US10208351B2 (en) 2013-10-18 2019-02-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) RNY-derived small RNAs as biomarkers for atherosclerosis-related disorders
CN110709074B (zh) 2017-05-15 2023-02-17 辛辛那提大学 通过直接施用辛伐他汀的一种或多种代谢物来治疗无血管软骨组织中的缺损的组合物和方法
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
ZA9610792B (en) * 1995-12-22 1997-07-09 Kowa Co Stabilized pharmaceutical composition
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor

Also Published As

Publication number Publication date
CA2364253A1 (en) 2000-09-14
AR022856A1 (es) 2002-09-04
PE20001559A1 (es) 2001-01-16
AU2866400A (en) 2000-09-28
JP2002538202A (ja) 2002-11-12
JP2000256191A (ja) 2000-09-19
CO5150193A1 (es) 2002-04-29
WO2000053173A1 (en) 2000-09-14
EP1161236A1 (en) 2001-12-12

Similar Documents

Publication Publication Date Title
SV2002000036A (es) Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
SV2002000035A (es) Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11121/rm/ta
HK1057899A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
HK1087702A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
MXPA04009352A (es) Terapia de combinacion para el tratamiento de la enfermedad de parkinson con inhibidores de ciclooxigenasa-2 (cox2).
CO5570677A2 (es) Quinolinilpirrolopirazoles
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2007126964A3 (en) Kinase inhibitors
WO2005016326A3 (en) Analogs of thalidomide as potential angiogenesis inhibitors
WO2003065982A3 (en) Engineering absorption of therapeutic compounds via colonic transporters
IL300151A (en) Combinations for the treatment of cancer
RU2008103617A (ru) Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
UA89035C2 (ru) Эфиры гидроксамовых кислот и их фармацевтическое применение
ECSP066878A (es) [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa
CY1106763T1 (el) Προληπτικα ή θεραπευτικα μεσα για φλεγμονωδεις νοσους του εντερου
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
ATE268174T1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
PT1150704E (pt) Melagatran para o tratamento da inflamacao
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
PL1750703T3 (pl) Sposób obniżania toksyczności żołądkowo-jelitowej powodowanej podawaniem tegafuru
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载